Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2018-04-04 Regulatory Filings
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvents partner ThromboGenics presenterar initiala data från en fas l/ll-studie av THR-317 hos patienter med diabetiskt makulaödem
Regulatory Filings Classification · 95% confidence The document is a press release dated April 4, 2018, announcing initial data from a Phase I/II study of THR-317 for diabetic macular edema, conducted by ThromboGenics, a partner of BioInvent International AB. It details safety and efficacy results (30% improvement in the 8mg group vs 5.3% in the 4mg group) and references a separate press release from the partner for more details. The concluding paragraph states: "Denna information är sådan information som BioInvent International AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning..." (This information is information that BioInvent International AB (publ) is required to disclose under the EU Market Abuse Regulation...). This structure—a brief announcement of material, time-sensitive information required for public disclosure under market regulations—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K or IR) but an announcement of specific operational/clinical data, and it doesn't fit perfectly into other specific categories like DIV, CAP, or MANG, it aligns best with an Earnings Release (ER) if the data is considered material financial/operational news, or RNS as a general regulatory disclosure. Given the focus on clinical trial data updates, which often accompany or substitute for quarterly earnings highlights, ER is a strong candidate, but RNS is the safest fallback for general regulatory disclosures not covered elsewhere. However, since it is a specific announcement of material results, ER (Earnings Release) is often used for such operational updates, even if not strictly quarterly earnings. Given the context of a clinical data update, it is a significant operational announcement. If it were purely a regulatory filing without specific results, RNS would be better. Since it contains key results, ER is appropriate, but RNS covers all mandatory regulatory disclosures not fitting other codes. I will classify it as RNS as it is a general regulatory announcement required by MAR, which is the broadest fit for mandatory disclosures not covered by specific financial report codes.
2018-04-04 Swedish
Annual Report 2017
Annual Report Classification · 100% confidence The document is titled '2017 Årsredovisning' (2017 Annual Report) and contains a comprehensive table of contents covering business highlights, management reports, financial statements (consolidated and parent company), audit reports, and governance information. It is a full-length annual report for the fiscal year 2017, not an announcement or a summary. FY 2017
2018-04-03 Swedish
Annual Report 2017
Annual Report Classification · 100% confidence The document is explicitly titled '2017 Annual Report' and contains comprehensive sections typical of such reports, including a CEO statement, strategy overview, project pipeline, consolidated financial statements (income statement, balance sheet, cash flows), and an auditor's report. It covers the full fiscal year 2017 and provides detailed financial and operational performance data, fitting the definition of a 10-K/Annual Report. FY 2017
2018-04-03 English
Ändring av antalet aktier och röster i BioInvent International AB
Share Issue/Capital Change Classification · 98% confidence The document is a short announcement dated March 29, 2018, titled "Ändring av antalet aktier och röster i BioInvent International AB" (Change in the number of shares and votes in BioInvent International AB). It explicitly states the total number of shares and votes following a directed share issue announced the previous day. This directly relates to a change in the company's capital structure (share count). This fits the definition of 'Share Issue/Capital Change' (SHA). It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Since it details a specific change in the number of shares resulting from a financing activity, SHA is the most precise classification.
2018-03-29 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding quantity and voting rights for a specific holder ('ABG Sundal Collier AB') concerning the issuer ('BioInvent International Aktiebolag'). It specifies the 'Reason for major shareholding notification' and provides 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights (13.04348%). This structure perfectly matches the definition of a Major Shareholding Notification.
2018-03-28 English
BioInvent har genomfört en riktad nyemission om cirka 85 miljoner kronor
Capital/Financing Update Classification · 99% confidence The document is a press release dated March 28, 2018, announcing that BioInvent International AB has successfully completed a directed new share issue ('riktad nyemission') raising approximately 85 million SEK. The text details the number of shares issued, the price, the use of proceeds (funding clinical development), and the resulting dilution. This activity directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing event itself.
2018-03-28 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.